Data on the combination with PD-1 in the adjuvant phase have not been reported, and the latest CheckMate-7FL [103] and KEYNOTE-756 trials [104] showed that the addition of PD-1 in high-risk ER+ /HER2- early-stage breast cancers significantly improved the pCR of neoadjuvant therapy. Here, ERBB2 is linked to breast cancer.